文献速递炎症性肠病

活动性溃疡性结肠炎激素减量:长疗程优于短疗程的随机对照试验

Clinical Trial: Long Versus Short Tapering of Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis-A Randomised Controlled Trial.
PubMed 文献 · Aliment Pharmacol Ther · 2026-01-02

该随机对照试验纳入94例初始激素治疗2周有应答的活动性溃疡性结肠炎患者,比较6周短疗程与10周长疗程激素减量方案,主要终点为6个月时无激素临床缓解。

要点

  • 活动性UC激素应答后,6周短减量方案6个月临床缓解率低于10周长减量方案。
  • 长短疗程复发率、内镜UCEIS及组织学Nancy评分无显著差异。
  • 两组不良事件(痤疮、肌病、情绪改变等)发生率相似。

核心结论

  • 在初始激素治疗2周有应答的活动性UC患者中,6周短减量方案在6个月临床缓解方面劣于10周长减量方案。

研究设计与样本

  • 随机对照试验,纳入94例活动性UC且初始激素治疗2周有应答的患者,随机分为长减量组48例和短减量组46例,并按急性重症UC分层。

主要发现

  • 中位UCEIS评分:长减量组3 vs 短减量组2(p=0.23),无显著差异。
  • Nancy评分:长减量组2(IQR 0-3)vs 短减量组1.5(IQR 0.75-3)(p=0.4),无显著差异。
  • 不良事件:痤疮14.58% vs 2.16%、肌病8.33% vs 6.52%、皮肤改变2.08% vs 2.17%、情绪改变0% vs 4.34%、血细胞减少0% vs 2.17%、头痛6.25% vs 6.52%,两组相似。

关键数值与推荐

  • 短减量总疗程6周,长减量总疗程10周。

临床怎么用

  • 对初始激素治疗有应答的中重度活动性UC患者,可优先考虑10周长减量方案以改善6个月无激素临床缓解。
  • 短减量方案并未显著增加复发率或不良事件,但临床缓解率较低,需个体化权衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Appropriate tapering strategy for corticosteroids in ulcerative colitis (UC) is uncertain. AIM: To compare the efficacy and safety of two steroid tapering regimens in patients with active UC. METHODS: We randomised patients with active UC with initial steroid response after 2 weeks to short (total 6 weeks) or long taper (total 10 weeks). Randomization was stratified for acute severe UC. The primary outcome was steroid-free clinical remission at 6 months. Secondary outcomes included assessment of symptomatic remission, relapse rate, endoscopic and histological scores, and safety. RESULTS: Of 94 patients (48 in long, 46 in short taper) randomised, short taper was inferior to long taper in inducing clinical remission at 6 months (RR = 2.19; CI 1.08-4.46; p = 0.02). The relapse rates were similar in the long (37%) and short taper (46%) arms (HR: 0.34; CI: 0.10-1.11; p = 0.42). The median UCEIS scores (3 vs. 2; p = 0.23) and Nancy scores [2 (IQR 0-3) vs. 1.5 (0.75-3); p = 0.4] were not different between arms. Adverse events in the long and short taper arms, such as acne (14.58% vs. 2.16%), myopathy (8.33% vs. 6.52%), skin changes (2.08% vs. 2.17%), mood changes (0% vs. 4.34%), cytopenia (0% vs. 2.17%), and headache (6.25% vs. 6.52%) were similar. CONCLUSION: A shorter taper duration of 6 weeks was inferior to a longer taper of 10 weeks in achieving clinical remission of UC at 6 months. TRIAL REGISTRATION: CTRI Number: CTRI/2021/06/034129.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Kumar A, Patil AN, Grewal J, et al. Clinical Trial: Long Versus Short Tapering of Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis-A Randomised Controlled Trial. Aliment Pharmacol Ther. 2026. PMID: 41482657. doi:10.1111/apt.70509

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。